Elixir Pharmaceuticals' Phase III Trial of Metformin-Mitiglinide Combination Therapy Demonstrates Significant Reductions in HbA1c (Blood Glucose) Levels Compared to Type 2 Diabetes Patients Not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback